Evidence map›Paper›PMID 28390584›Full record

ArticleAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2017

Live attenuated influenza vaccine use and safety in children and adults with asthma.

Jonathan Duffy, Melissa Lewis, Theresa Harrington, Roger Baxter, Edward A Belongia, Lisa A Jackson, Steven J Jacobsen, Grace M Lee, Allison L Naleway, James Nordin and 2 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Jonathan DuffyImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: jduffy@cdc.gov.
Melissa LewisImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia.
Theresa HarringtonImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia.
Roger BaxterKaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California.
Edward A BelongiaMarshfield Clinic Research Foundation, Marshfield, Wisconsin.
Lisa A JacksonGroup Health Research Institute, Seattle, Washington.
Steven J JacobsenKaiser Permanente Southern California, Pasadena, California.
Grace M LeeHarvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
Allison L NalewayCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon.
James NordinHealthPartners Institute, Minneapolis, Minnesota.
Matthew F DaleyInstitute for Health Research, Kaiser Permanente Colorado, Denver, Colorado.
Vaccine Safety Datalink
Kaiser Permanente · USCenters for Disease Control and Prevention · USHarvard University · USHealthPartners · USKaiser Permanente Center for Health Research · USKaiser Permanente Washington Health Research Institute · USMarshfield Clinic · USNational Center for Immunization and Respiratory Diseases · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundLive attenuated influenza vaccine (LAIV) might increase the risk of wheezing in persons with asthma or children younger than 5 years with a history of recurrent wheezing.

objectiveTo describe the use and assess the safety of LAIV in persons with asthma in the Vaccine Safety Datalink population.

methodsWe identified persons with asthma using diagnosis codes and medication records in 7 health care organizations over 3 influenza seasons (2008-2009 through 2010-2011) and determined their influenza vaccination rates. Using the self-controlled risk interval method, we calculated the incidence rate ratio of medically attended respiratory events in the 14 days after LAIV compared with 29 to 42 days after vaccination in persons 2 through 49 years old.

resultsIn our population of 6.3 million, asthma prevalence was 5.9%. Of persons with asthma, approximately 50% received any influenza vaccine but less than 1% received LAIV. The safety study included 12,354 LAIV doses (75% in children; 93% in those with intermittent or mild persistent asthma). The incidence rate ratio for inpatient and emergency department visits for lower respiratory events (including asthma exacerbation and wheezing) was 0.98 (95% confidence interval 0.63-1.51) and the incidence rate ratio for upper respiratory events was 0.94 (95% confidence interval 0.48-1.86). The risk of lower respiratory events was similar for intermittent and mild persistent asthma, across age groups, and for seasonal trivalent LAIV and 2009 H1N1 pandemic monovalent LAIV.

conclusionLAIV use in asthma was mostly in persons with intermittent or mild persistent asthma. LAIV was not associated with an increased risk of medically attended respiratory adverse events.

Indexed as

AdolescentAdultAsthmaChildChild, PreschoolFemaleHospitalizationHumansIncidenceInfluenza, HumanInfluenza VaccinesMaleMiddle AgedPopulation SurveillancePrevalenceRespiratory SoundsInfluenza VaccinesVaccines, Attenuated

Identifiers

PMID28390584
PMCPMC6674979
OpenAlexW2604860767

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.